ALNY News and Press, Alnylam Pharmaceuticals Inc. From 06/13/23

2023-06-13 17:55:37 ET Summary Regeneron Pharmaceuticals, Inc. has potential to receive FDA approval of higher dosing of 8 mg of EYLEA, which has been set with an FDA target action date of June 27, 2023. The additional indication in preterm infants with retinopathy of prematurity ...

2023-06-11 12:00:02 ET Driven by novel therapeutics from Biogen ( NASDAQ: BIIB )/ Eisai ( OTCPK:ESALF ) and Eli Lilly ( NYSE: LLY ), the Alzheimer’s disease market across eight major countries will reach $13.7B in 2030, the data analytics firm, GlobalData said las...

2023-06-07 07:07:57 ET Promosome LLC became the latest to stake a claim to the groundbreaking messenger-RNA-based vaccine technology when the New York-based biotech filed a lawsuit against Pfizer ( PFE ), BioNTech ( BNTX ), and Moderna ( NASDAQ: MRNA ) on Tuesday in a Califo...

2023-06-06 05:52:09 ET Summary Alnylam Pharmaceuticals reports a 48% increase in net product revenue in Q1 2023, driven by the launch of Amvuttra and increased patients on Givlaari and Oxlumo therapies. The company's collaboration with Regeneron Pharmaceuticals on the ALN-APP prog...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Goldman Sachs 44 th Annual Global Healthcare Conference on Monday, June 12, 2023 at 8:00 am PT (11:00 am ET) at the Waldorf Astoria Mon...

2023-05-22 17:43:28 ET Summary BioNTech SE has initiation of a phase 3 study using BNT316 as a monotherapy for PD-1/PD-L1 refractory non-small cell lung cancer patients that is expected to take place in 2023. Updated results from the expansion cohort from phase 1/2 study using BNT...

– Continued Treatment with Patisiran in Open-Label Extension Period Showed Evidence of Sustained Benefit across Measures of Functional Capacity and Health Status and Quality of Life, as well as Cardiac Stress and Injury, through 18 Months – – Safety Profil...

2023-05-14 12:00:49 ET Leqembi, the new Alzheimer's therapy developed by Biogen ( NASDAQ: BIIB ) and Eisai ( OTCPK:ESALF ) ( OTCPK:ESAIY ), could add $2B - $5B costs to Medicare annually, in the event of broader coverage, according to a recently published study. Early th...

2023-05-04 21:05:51 ET Summary Baillie Gifford’s 13F portfolio value increased from ~$96B to ~$111B this quarter. They increased Advanced Micro Devices, Duolingo, and Meta Platforms while reducing Elevance Health, Alphabet, AJ Gallagher & Co, and Booking Holdings. T...

2023-05-04 12:22:09 ET Alnylam Pharmaceuticals, Inc. (ALNY) Q1 2023 Earnings Conference Call May 4, 2023 8:30 AM ET Company Participants Christine Lindenboom – Senior Vice President-Investor Relations and Corporate Communication Yvonne Greenstreet – Chi...